Sheng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sheng Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chenfeng Hua
A Key Laboratory of Tobacco Chemistry , Zhengzhou Tobacco Research Institute of CNTC , Zhengzhou , China
1 shared publication- Fuwei Xie
Department of Plastic Surgery Henan Provincial People's Hospital (Zhengzhou University People's Hospital) Zhengzhou China
1 shared publication - Ge Zhao
Animal Product Safety Laboratory, China Animal Health And Epidemiology Center, Qingdao, China
1 shared publication - Huanzhou Xue
Department of Hepatobiliary, The People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China
1 shared publication - Huiting Wang
Department of Neurology, Liaocheng People’s Hospital, Liaocheng, Shandong, China
1 shared publication Jiakun Su
D China Tobacco Jiangxi Industrial LLC , Nanchang , China
1 shared publication
Latest Publications
- 28 May 2019
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 29 (7) , 499-510
Analysis of methyl DNA adducts and metabolites in BEAS-2B cells induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is classified as a Group 1 human carcinogen. It is metabolically activated by P450 enzymes to intermediate methylate and pyridyloxobutylate DNA, resulting in the formation of DNA adduct that is critical for the carcinogenicity of NNK. To directly and objectively examine the DNA adduct formation profiles without the complexity of factors in vivo, in the present study, five kinds of methyl DNA adducts were first identified in the incubation model of NNK established with human lung epithelial cells (BEAS-2B). The level of methyl DNA adducts and metabolites of NNK were quantitatively analyzed, respectively. With the increase of exposure time and dose, the level of methyl DNA adducts and metabolites increased. Furthermore, with the changes of the activity of P450 enzymes, which is the main enzyme regulating the α-hydroxylation of NNK, we found the levels of both methyl adducts and metabolites formed via α-hydroxylation in experimental groups showed the same trend compared with those in control group, while the metabolites formed via other pathways changed in the opposite trend. The result proves that the methyl adducts induced by NNK generate via α-hydroxylation pathway in BEAS-2B cells.
- 28 May 2019
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 29 (7) , 499-510
Analysis of methyl DNA adducts and metabolites in BEAS-2B cells induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is classified as a Group 1 human carcinogen. It is metabolically activated by P450 enzymes to intermediate methylate and pyridyloxobutylate DNA, resulting in the formation of DNA adduct that is critical for the carcinogenicity of NNK. To directly and objectively examine the DNA adduct formation profiles without the complexity of factors in vivo, in the present study, five kinds of methyl DNA adducts were first identified in the incubation model of NNK established with human lung epithelial cells (BEAS-2B). The level of methyl DNA adducts and metabolites of NNK were quantitatively analyzed, respectively. With the increase of exposure time and dose, the level of methyl DNA adducts and metabolites increased. Furthermore, with the changes of the activity of P450 enzymes, which is the main enzyme regulating the α-hydroxylation of NNK, we found the levels of both methyl adducts and metabolites formed via α-hydroxylation in experimental groups showed the same trend compared with those in control group, while the metabolites formed via other pathways changed in the opposite trend. The result proves that the methyl adducts induced by NNK generate via α-hydroxylation pathway in BEAS-2B cells.
- 15 January 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 10421-10433
microRNA‐135a protects against myocardial ischemia‐reperfusion injury in rats by targeting protein tyrosine phosphatase 1B
MicroRNAs are an emerging class of molecules that regulate pathogenesis of cardiovascular diseases. Here we aim to elucidate the effects and mechanism of miR‐135a, a previously reported regulator of ischemia‐reperfusion (I/R) injury, in myocardial I/R injury. Quantitative real‐time polymerase chain reaction analysis revealed that the expression level of miR‐135a was significantly decreased both in the rat I/R group and H9c2 cells subjected to hypoxia/reoxygenation. Overexpression of miR‐135a in vivo markedly decreased the infarct size and inhibited the I/R‐induced cardiomyocyte apoptosis. Overexpression of miR‐135a in H9c2 also exerted antiapoptosis effects. Furthermore, bioinformatics analysis, luciferase activity, and the Western blot assay indicated that protein tyrosine phosphatase 1B (PTP1B) is a direct target of miR‐135a. In addition, the expression of proapoptotic‐related genes, such as p53, Bax, and cleaved caspase3, were decreased in association with the downregulation of PTP1B. In summary, this study demonstrates that miR‐135a exerts protective effects against myocardial I/R injury by targeting PTP1B.
- 15 January 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 10421-10433
microRNA‐135a protects against myocardial ischemia‐reperfusion injury in rats by targeting protein tyrosine phosphatase 1B
MicroRNAs are an emerging class of molecules that regulate pathogenesis of cardiovascular diseases. Here we aim to elucidate the effects and mechanism of miR‐135a, a previously reported regulator of ischemia‐reperfusion (I/R) injury, in myocardial I/R injury. Quantitative real‐time polymerase chain reaction analysis revealed that the expression level of miR‐135a was significantly decreased both in the rat I/R group and H9c2 cells subjected to hypoxia/reoxygenation. Overexpression of miR‐135a in vivo markedly decreased the infarct size and inhibited the I/R‐induced cardiomyocyte apoptosis. Overexpression of miR‐135a in H9c2 also exerted antiapoptosis effects. Furthermore, bioinformatics analysis, luciferase activity, and the Western blot assay indicated that protein tyrosine phosphatase 1B (PTP1B) is a direct target of miR‐135a. In addition, the expression of proapoptotic‐related genes, such as p53, Bax, and cleaved caspase3, were decreased in association with the downregulation of PTP1B. In summary, this study demonstrates that miR‐135a exerts protective effects against myocardial I/R injury by targeting PTP1B.